Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

[5] Pinke KH, et al. Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? Neurotherapeutics. 2020 Jan;17(1):218-234. [6] Brown MA, Weinberg RB. Mast Cells and ...

Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

Rich nations hold millions of mpox vaccines as Africa grapples with an outbreak, while the US FDA approves Roche's multiple ...

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...

A pharmaceutical and a nonprofit are teaming up to evaluate segesterone acetate as a possible MS therapy to restore lost myelin in patients.

New research highlights the benefits of starting monoclonal antibody therapy for multiple sclerosis in childhood. The study, ...

The study, which utilised data from the French MS Registry, Italian MS Register, and the global MSBase Registry, analysed the outcomes of 282 patients with paediatric-onset MS.